Today we had the honor of interviewing Ana Marquez, President at Marquez Clinical Site Partners. Ana has a tremendous understanding of how research clinics should operate, both from a clinical operations standpoint as well as from a business standpoint. In this all encompassing interview, Ana and the Gurus delve into the topic of Research Clinics and Money. Pretty much anything you can think of or any question you may have ever had regarding how clinical trial clinics get or should get paid is covered here. We definitely need to do a part 2 of this interview but we encourage you to learn as much as you can from this conversation.
Today Dan and Don answer a viewer’s question regarding opening a second research clinic. When should you do this if ever, and how would one now when the time is right to expand in clinical trials? We hope you find this helpful!
Today we interviewed Phill Jones of AsisChem. In this interview we approached clinical trials from a pre-clinical perspective, which is what Phill is very knowledgeable on. It is important to understand that before clinical trials ever begin on a molecule that the molecule must first be synthesized. This is where Phill and his company come into the picture. We will definitely do a part 2 of this interview due to the poor audio quality towards the end of the video. We hope you can still gain some greater insight on this topic! You may also reach Phill at firstname.lastname@example.org or on LinkedIn. Phile also recommends you check out these websites as well: The Journal of Visualized Experiments (JoVE), the world’s first peer-reviewed video journal.
We were shocked to recently find out that the Indian government has recently put a hold on all USA sponsored clinical trials in India. While the situation is still unclear, we have heard through the grapevine that due to several negative articles portraying some ethical issues involving US Pharma companies and clinical trial incidents in India that further investigation will be required before India will allow these clinical trials to resume. Either way, in this video we discuss what implications this could have on US reserach clinics and clinical trials in general. What are your thoughts on this?
Today we interviewed Carlton Hoyt, CEO of LifeSciSoft, and also Principal Consultant at BioBM Consulting. Carlton brings a wealth of knowledge to the table and we discuss academia’s involvement in clinical trials, his story on how he got started in this industry, and how a PhD scientist became a successful entrepreneur thanks to clinical trials. Carlton understands that social media can play a huge role in the development of his companies and he has set up a fantastic blog on his company’s website. We hope you all can gain some better insight into the clinical trials industry.
We received a question recently from one of our viewers who had a question regarding how clinical research clinics actually get paid when they conduct clinical trials. We thought it would be pretty transparent of us to disclose how we get paid at SCCT. Note that this explanation we give applies to only the private research clinics out there and not the federally funded, NIH supported academic or non profit research clinics. Let us know what you think and for another view on this check out our viewer, Stephany’s, blog post on this.